Theophylline NDC 27241-272

NDC codes

FDA NDC Directory

Product NDC (as listed)27241-272Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27241-0272Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27241-272-01	27241027201	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-272-01)Marketed from Mar 26, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Theophylline
Generic name (nonproprietary): theophylline
Active ingredients: Theophylline anhydrous — 300 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Ajanta Pharma USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 218401
Marketing start: Mar 26, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Xanthines (Chemical structure)
Identifiers: Product ID 27241-272_fbec14fb-bd76-48e7-b61f-b19cd1a3ea2fSPL ID fbec14fb-bd76-48e7-b61f-b19cd1a3ea2fSPL set ID 7a422c32-bbdf-4297-84f4-9c438c904b0cRxCUI 314241, 317769UNII 0I55128JYKUPC 0327241273018, 0327241272011
Pharmacologic class: Methylxanthine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427241027201 followed by a unit qualifier and the quantity

Package 27241-0272-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 30, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 218401

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 218401
Product	Strength	Form · route	Labeler	Product NDC
Theophylline	Theophylline anhydrous 450 mg/1	Tablet, Extended releaseOral	Ajanta Pharma USA Inc.	27241-273